The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ermilov V.V.

Volgograd State Medical University

Nesterova A.A.

Volgograd State Medical University

Amyloidogenesis and neurotrophic dysfunction in age-related macular degeneration in correlation with Alzheimer’s disease

Authors:

Ermilov V.V., Nesterova A.A.

More about the authors

Read: 729 times


To cite this article:

Ermilov VV, Nesterova AA. Amyloidogenesis and neurotrophic dysfunction in age-related macular degeneration in correlation with Alzheimer’s disease. Russian Journal of Archive of Pathology. 2025;87(6):61‑68. (In Russ.)
https://doi.org/10.17116/patol20258706161

Recommended articles:
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20
Features of facial expressions in patients with cognitive impairment due to Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):104-109

References:

  1. Ermakova NA, Rabdanova OTs. Main etiological factors and pathogenetic mechanisms of age-related macular degeneration. Klinicheskaya oftal’mologiya. 2007;8(3):125-128. (In Russ.).
  2. Johnson LV, Leitner WP, Rivest AJ, et al. The Alzheimer’s A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99(18):11830-11835. https://doi.org/10.1073/pnas.192203399
  3. Muraleva NA, Kozhevnikova OS, Fursova AZ, Kolosova NG. Suppression of AMD-Like Pathology by Mitochondria-Targeted Antioxidant SkQ1 Is Associated with a Decrease in the Accumulation of Amyloid β and in mTOR Activity. Antioxidants (Basel). 2019;8(6):177.  https://doi.org/10.3390/antiox8060177
  4. Armstrong RA. The pathogenesis of Alzheimer’s disease: a reevaluation of the «amyloid cascade hypothesis». Int J Alzheimers Dis. 2011;201:630865. https://doi.org/10.4061/2011/630865
  5. Serov VV. Senile amyloidosis: from Schwartz’s tetrad to the present day. RMZh. 1997;20:8. (In Russ.).
  6. Lübke JH, Idoon F, Mohasel-Roodi M, et al. Neurotrophic factors in Alzheimer’s disease: pathogenesis and therapy. Acta Neurobiol Exp (Wars). 2021;81(4):314-327. PMID: 35014981 
  7. Vetter AR. Aloys Rudolph Vetter‘s Aphorismen aus der pathologischen Anatomie. Gassler, 1803; T. 1. 
  8. Rameev VV, Lysenko LV. History of the study of amyloidosis: from the Rokitansky’s theory to the present day. Ter Arkh. 2024;96(6): 635-640.  https://doi.org/10.26442/00403660.2024.06.202732
  9. Strukov AI, Serov VV, Pavlikhina LV. On the pathogenesis of amyloidosis. Virchows Arch Pathol Anat Physiol Klin Med. 1963;336: 550-563.  https://doi.org/10.1007/BF01003620
  10. Teilum G. Periodic acid-Schiff-positive reticulo-endothelial cells producing glycoprotein; functional significance during formation of amyloid. The Am J of Pathol. 1956;32(5):945-959. 
  11. Serov VV, Gritsman AI. Amyloidosis: tissue dysproteinosis or a tumor? Sov Med. 1975;7:13-18. (In Russ.).
  12. Rameev VV. Systemic amyloidosis at the present stage: the role of kidney damage in disease progression, ways to optimize diagnosis and improve prognosis: diss. ... doctor of medical sciences. 2020;228. (In Russ.).
  13. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209-213.  https://doi.org/10.1080/13506129.2016.1257986
  14. Shelkovnikova TA, Kulikova AA, Tsvetkov FO, et al. Proteinopathies — forms of neurodegenerative diseases based on pathological protein aggregation. Molekulyarnaya biologiya. 2012;46(3):402-414. (In Russ.). https://doi.org/10.1134/S0026893312020161
  15. Ermilov V, Makhonina O. The role of retinal pigment epithelium cells in amyloidogenesis of senile local eye amyloidosis with age-related macular degeneration. Virchows Archiv-European Journal of Pathology. 2011;459.S1:190. 
  16. Ermilov VV. Senile ocular amyloidosis as a manifestation of senile cerebral amyloidosis. Russian Journal of Archive of Pathology. 1993;55(6):39-42. (In Russ.).
  17. Ermilov VV, Serov VV. The place of ocular amyloidosis among various forms of amyloidosis. Russian Journal of Archive of Pathology. 1994;56(4):9-14. (In Russ.).
  18. Anisimov VN. Molecular and physiological mechanisms of aging: In 2 volumes. 2nd ed., revised and expanded. St. Petersburg: Nauka. 2008;434. (In Russ.).
  19. Khavinson VKh, Anisimov SV. Peptide regulation of genome and aging. M.: Russian Academy of Medical Sciences. 2008;208. (In Russ.).
  20. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355(14):1474-1485. https://doi.org/10.1056/NEJMra062326
  21. Nesterova AA, Zagreebin VL. Retinal aging (degeneration, regression, apoptosis) and its connection with geronto-ophthalmological diseases. Volgogradskii nauchno-meditsinskii zhurnal. 2012;(1): 90-93. (In Russ.).
  22. Davydovskiy IV. Gerontology. M.: Meditsina. 1966;297. (In Russ.).
  23. Golubev AG. Biologiya prodolzhitel’nosti zhizni. St. Petersburg: N.-L.; 2009;287. (In Russ.).
  24. Ermilov VV, Nesterova AA. β-amyloidopathy in the Pathogenesis of Age-Related Macular Degeneration in Correlation with Neurodegenerative Diseases. Adv Exp Med Biol. 2016;854:119-125.  https://doi.org/10.1007/978-3-319-17121-0_17
  25. Ermilov VV, Nesterova AA, Makhonina OV. Age-related macular degeneration and neurodegenerative diseases (clinical-morphological and pathogenetic parallels). Klinicheskaya gerontologiya. 2013;19(11-12):36-44. (In Russ.).
  26. Nesterova AA, Ermilov VV. Is age-related macular degeneration a manifestation of Alzheimer’s disease? Advances in gerontology. 2015;28(1):42-47. (In Russ.).
  27. Rameev VV, Kozlovskaya LV. Amyloidosis: modern methods of diagnosis and treatment. Effektivnaya farmakoterapiya. 2012;(44): 6-15. (In Russ.).
  28. Ermilov VV, Tyurenkov IN, Nesterova AA, Zagreebin VL. Alzheimer’s disease and geronto-ophthalmological diseases in the aspect of amyloidogenesis. Russian Journal of Archive of Pathology. 2013;75(2):37-42. (In Russ.).
  29. Dolzhikov AA, Bobyntsev II, Belykh AE, et al. Pathogenesis of neurodegenerative pathology and new concepts of transport-metabolic systems of the brain and eye. Chelovek i ego zdorov’e. 2020;1:43-57. (In Russ.). https://doi.org/10.21626/vestnik/2020-1/06
  30. Nasrolahi A, Javaherforooshzadeh F, Jafarzadeh-Gharehziaaddin M, et al. Therapeutic potential of neurotrophic factors in Alzheimer’s Disease. Mol Biol Rep. 2022;49(3):2345-2357. https://doi.org/10.1007/s11033-021-06968-9
  31. Gao L, Zhang Y, Sterling K, Song W. Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Transl Neurodegener. 2022;11(1):4.  https://doi.org/10.1186/s40035-022-00279-0
  32. Faustino C, Rijo P, Reis CP. Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer’s disease. Pharmacol Res. 2017;120:68-87.  https://doi.org/10.1016/j.phrs.2017.03.020
  33. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11(5):551-555.  https://doi.org/10.1038/nm1239
  34. Eriksdotter-Jönhagen M, Linderoth B, Lind G, et al. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(1):18-28.  https://doi.org/10.1159/000336051
  35. Ermilov VV, Nesterova AA. β-amyloidopathy in the Pathogenesis of Age-Related Macular Degeneration in Correlation with Neurodegenerative Diseases. Adv Exp Med Biol. 2016;854:119-125.  https://doi.org/10.1007/978-3-319-17121_017
  36. Mathieu E, Gupta N, Ahari A, et al. Evidence for Cerebrospinal Fluid Entry Into the Optic Nerve via a Glymphatic Pathway. Invest Ophthalmol Vis Sci. 2017;58(11):4784-4791. https://doi.org/10.1167/iovs.17-22290
  37. Gulisano W, Maugeri D, Baltrons MA, et al. Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade. J Alzheimers Dis. 2018;64(1):611-631.  https://doi.org/10.3233/JAD-179935
  38. Kimura T, Jia J, Claude-Taupin A, et al. Cellular and molecular mechanism for secretory autophagy. Autophagy. 2017;13(6): 1084-1085. https://doi.org/10.1080/15548627.2017.1307486
  39. Allen SJ, Watson JJ, Dawbarn D. The neurotrophins and their role in Alzheimer’s disease. Curr Neuropharmacol. 2011;9(4):559-573.  https://doi.org/10.2174/157015911798376190
  40. Iulita MF, Cuello AC. Nerve growth factor metabolic dysfunction in Alzheimer’s disease and Down syndrome. Trends Pharmacol Sci. 2014;35(7):338-348.  https://doi.org/10.1016/j.tips.2014.04.010
  41. Aghourian M, Legault-Denis C, Soucy JP, et al. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV. Mol Psychiatry. 2017;22(11):1531-1538. https://doi.org/10.1038/mp.2017.183
  42. Xi L. Combination of pigment epithelium derived factor with anti-vascular endothelial growth factor therapy protects the neuroretina from ischemic damage. Biomed Pharmacother. 2022;151:113-113.  https://doi.org/10.1016/j.biopha.2022.113113
  43. Chai AB, Lam HHJ, Kockx M, Gelissen IC. Apolipoprotein E isoform-dependent effects on the processing of Alzheimer’s amyloid-β. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(9):158980. https://doi.org/10.1016/j.bbalip.2021.158980
  44. Andersen OM, Reiche J, Schmidt V, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102(38):13461-13466. https://doi.org/10.1073/pnas.0503689102
  45. Glerup S, Lume M, Olsen D, et al. SorLA controls neurotrophic activity by sorting of GDNF and its receptors GFRα1 and RET. Cell Rep. 2013;3(1):186-199.  https://doi.org/10.1016/j.celrep.2012.12.011
  46. Capsoni S, Amato G, Vignone D, et al. Dissecting the role of sortilin receptor signaling in neurodegeneration induced by NGF deprivation. Biochem Biophys Res Commun. 2013;431(3):579-585.  https://doi.org/10.1016/j.bbrc.2013.01.007
  47. De Rossi P, Nomura T, Andrew RJ, et al. Neuronal BIN1 Regulates Presynaptic Neurotransmitter Release and Memory Consolidation. Cell Rep. 2020;30(10):3520-3535. https://doi.org/10.1016/j.celrep.2020.02.026

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.